Meeting
2018 ASCO Annual Meeting
Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study.
Authors
Daniel Pink
Helios Klinikum Bad Saarow, Bad Saarow, Germany
Daniel Pink , Sebastian Bauer , Thomas Brodowicz , Peter Reichardt , Bernd Kasper , Stephan Richter , Peter Hohenberger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02212015
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11570)
DOI
10.1200/JCO.2018.36.15_suppl.11570
Abstract #
11570
Poster Bd #
315
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.
First Author: Vanessa Anne Eulo
Poster
2020 ASCO Virtual Scientific Program
Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
First Author: Christine H. Chung
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).
First Author: Matthew Ingham